Robot
21.Mar.25 2:54 AM

Energy Vault Holdings Inc. Stock Price Drops Following Fourth-Quarter Earnings and Revenue Miss

Energy Vault Holdings Inc. (NRGV) shares are trading lower on Thursday following the company's fourth-quarter earnings and revenue miss. The company attributed the shortfall to declining lithium-ion battery prices, the timing of revenue recognition for projects in Australia, and its decision to retain $100 million in projects on its balance sheet instead of recognizing them as revenue.
Robot
21.Mar.25 2:46 AM

Mixed Results as Profit Falls Short but Revenue Exceeds Expectations

FedEx Corp. (FDX) reported mixed results for its third quarter, falling short of analyst expectations on earnings but exceeding them on revenue. The company reported earnings of $4.51 per share, missing the consensus estimate of $4.54, while revenue came in at $22.2 billion, surpassing the $21.89 billion estimate.
Robot
21.Mar.25 2:35 AM

Micron Technology Inc. Reports Strong Second Quarter Results, Exceeds Analyst Expectations

Micron Technology Inc. (MU) surpassed analyst expectations in its second quarter, reporting revenue of $8.05 billion and adjusted earnings per share of $1.56. The company anticipates record quarterly revenue in fiscal Q3 and is on track for record revenue and significantly improved profitability in fiscal 2025.
Robot
21.Mar.25 2:26 AM

Peter Schiff Warns of "Scam" Bitcoin Reserve, Predicts Crypto Losses Under Trump's Influence

Peter Schiff, a prominent Bitcoin critic, warns that the strategic Bitcoin reserve is a tool to trick Americans into speculative losses. He specifically criticizes President Donald Trump's involvement in promoting cryptocurrencies, predicting that more Americans will lose money in crypto under his influence than in any other speculative mania in history.
Robot
21.Mar.25 2:12 AM

A Promising Contender in the NSCLC Treatment Landscape

B. Riley Securities initiated coverage on ArriVent Biopharma, a clinical-stage biopharmaceutical company focused on developing cancer treatments. The firm believes ArriVent's lead drug candidate, firmonertinib, has the potential to be a superior treatment option for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations and PACC mutations, representing a significant market opportunity.